| Androxal (enclomifene) / AbbVie |
ZA-003Ext, NCT01067365: Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism |
|
|
| Completed | 3 | 104 | US | Androxal, Enclomiphene citrate | Repros Therapeutics Inc. | Secondary Hypogonadism | 05/07 | 05/07 | | |
ZA-003, NCT00962637: Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism |
|
|
| Completed | 3 | 194 | US | Androxal, Enclomiphene citrate, AndroGel, Placebo | Repros Therapeutics Inc. | Secondary Hypogonadism | 05/07 | 05/07 | | |
NCT01532414: Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism |
|
|
| Completed | 3 | 151 | US | Androxal, Enclomiphene citrate, Placebo, Dummy | Repros Therapeutics Inc. | Secondary Hypogonadism | 03/13 | 03/13 | | |
NCT01739595: Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism |
|
|
| Completed | 3 | 181 | US | enclomiphene citrate, Androxal, Placebo, Dummy | Repros Therapeutics Inc. | Secondary Hypogonadism | 09/13 | 09/13 | | |
NCT01534208: Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism |
|
|
| Completed | 3 | 499 | US | Androxal, Enclomiphene citrate | Repros Therapeutics Inc. | Secondary Hypogonadism | 10/13 | 10/13 | | |
NCT01739582: An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism |
|
|
| Completed | 3 | 300 | US | Androxal, enclomiphene citrate | Repros Therapeutics Inc. | Secondary Hypogonadism | 04/14 | 04/14 | | |
NCT01993225: A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% |
|
|
| Completed | 3 | 120 | US | Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel | Repros Therapeutics Inc. | Secondary Hypogonadism | 08/14 | 08/14 | | |
NCT01619683: Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism |
|
|
| Completed | 3 | 300 | US | enclomiphene citrate, Androxal, Placebo | Repros Therapeutics Inc. | Effect of Treatment on Bone Mineral Density | 09/14 | 09/14 | | |
NCT01993212: A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% |
|
|
| Completed | 3 | 120 | US | Androxal 12.5 mg or 25 mg, AndroGel 1.62%, Placebo Capsules, Placebo Gel | Repros Therapeutics Inc. | Secondary Hypogonadism | 09/14 | 09/14 | | |
